GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons

Cardiovascular Research

Volumn 89, Issue 1, 2011, Pages 72-78

  Griffioen, Kathleen J ^a   Wan, Ruiqian ^a   Okun, Eitan ^a   Wang, Xin ^b   Lovett Barr, Mary Rachael ^b   Li, Yazhou ^a   Mughal, Mohamed R ^a   Mendelowitz, David ^b   Mattson, Mark P ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Glucagon like peptide 1; Medulla; Nucleus ambiguus; Parasympathetic; Vagus

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUTAMIC ACID; GLYCINE;

AMBIGUUS NUCLEUS; ANIMAL EXPERIMENT; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ELECTROCARDIOGRAM; EXCITATORY JUNCTION POTENTIAL; FREQUENCY MODULATION; HEART; HEART FUNCTION; HEART RATE; HEART RATE VARIABILITY; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PREGANGLIONIC NERVE CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SPECTRAL SENSITIVITY; TELEMETRY; VAGUS NERVE;

ANIMALS; HEART; HEART RATE; MALE; MICE; PARASYMPATHETIC NERVOUS SYSTEM; PEPTIDES; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; VAGUS NERVE; VENOMS;

EID: 78650507366     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq271     Document Type: Article

References (49)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007;87:1409-1439.
2. Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 1985;28:704-707.
3. De Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 2008;51:2263-2270.
4. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003;26:2835-2841.
5. Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 2003;284:E1072-1079.
6. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72. (Pubitemid 26008136)
7. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003;23: 2939-2946.
8. Holmes GM, Browning KN, Tong M, Qualls-Creekmore E, Travagli RA. Vagally mediated effects of glucagon-like peptide 1: in vitro and in vivo gastric actions. J Physiol 2009;587:4749-4759.
9. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002;300:958-966.
10. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002;110:43-52.
11. Barragan JM, Eng J, Rodriguez R, Blazquez E. Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol 1999;277:E784-E791.
12. Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP et al. Pharmaco-kinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. J Clin Pharmacol 2008;48:1389-1399.
13. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P et al. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 2010;9:6.
14. Bharucha AE, Charkoudian N, Andrews CN, Camilleri M, Sletten D, Zinsmeister AR et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008;295:R874-R880.
15. Cabou C, Campistron G, Marsollier N, Leloup C, Cruciani-Guglielmacci C, Penicaud L et al. Brain glucagon-like peptide-1 regulates arterial blood flow, heart rate, and insulin sensitivity. Diabetes 2008;57:2577-2587.
16. Loewy AD, Spyer KM. Central Regulation of Autonomic Functions. Oxford: Oxford University Press; 1990.
17. Mendelowitz D. Firing properties of identified parasympathetic cardiac neurons in nucleus ambiguus. Am J Physiol 1996;271:H2609-H2614.
18. Wang J, Irnaten M, Neff RA, Venkatesan P, Evans C, Loewy AD et al. Synaptic and neurotransmitter activation of cardiac vagal neurons in the nucleus ambiguus. Ann N Y Acad Sci 2001;940:237-246. (Pubitemid 32623397)
19. Frank JG, Jameson HS, Gorini C, Mendelowitz D. Mapping and identification of GABAergic neurons in transgenic mice projecting to cardiac vagal neurons in the nucleus ambiguus using photo-uncaging. J Neurophysiol 2009;101:1755-1760.
20. Neff RA, Mihalevich M, Mendelowitz D. Stimulation of NTS activates NMDA and non-NMDA receptors in rat cardiac vagal neurons in the nucleus ambiguus. Brain Res 1998;792:277-282.
21. Larsen PJ, Tang-Christensen M, Holst JJ, Orskov C. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 1997;77:257-270.
22. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010;11:31-39.
23. Frontoni S, Bracaglia D, Gigli F. Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes. Nutr Metab Cardiovasc Dis 2005;15: 441-449.
24. Teuscher A, Egger M, Herman JB. Diabetes and hypertension. Blood pressure in clinical diabetic patients and a control population. Arch Intern Med 1989;149: 1942-1945.
25. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007;30:162-172. (Pubitemid 46052519)
26. Wan R, Camandola S, Mattson MP. Intermittent food deprivation improves cardiovascular and neuroendocrine responses to stress in rats. J Nutr 2003;133: 1921-1929.
27. Hayes MR, Skibicka KP, Grill HJ. Caudal brainstem processing is sufficient for behavioral, sympathetic, and parasympathetic responses driven by peripheral and hindbrain glucagon-like-peptide-1 receptor stimulation. Endocrinology 2008;149:4059-4068.
28. Thireau J, Zhang BL, Poisson D, Babuty D. Heart rate variability in mice: a theoretical and practical guide. Exp Physiol 2008;93:83-94.
29. Mendelowitz D, Kunze DL. Identification and dissociation of cardiovascular neurons from the medulla for patch clamp analysis. Neurosci Lett 1991;132:217-221.
30. Wan S, Coleman FH, Travagli RA. Glucagon-like peptide-1 excites pancreas-projecting preganglionic vagal motoneurons. Am J Physiol 2007;292:G1474-G1482.
31. Gaisano GG, Park SJ, Daly DM, Beyak MJ. Glucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons. Neurogastroenterol Motil 2010;22:470-479, e111.
32. Riediger T, Eisele N, Scheel C, Lutz TA. Effects of glucagon-like peptide 1 and oxynto-modulin on neuronal activity of ghrelin-sensitive neurons in the hypothalamic arcuate nucleus. Am J Physiol Regul Integr Comp Physiol 2010;298:R1061-R1067.
33. Acuna-Goycolea C, van den Pol A. Glucagon-like peptide 1 excites hypocretin/orexin neurons by direct and indirect mechanisms: implications for viscera-mediated arousal. J Neurosci 2004;24:8141-8152.
34. Laude D, Baudrie V, Elghozi JL. Effects of atropine on the time and frequency domain estimates of blood pressure and heart rate variability in mice. Clin Exp Pharmacol Physiol 2008;35:454-457.
35. Just A, Faulhaber J, Ehmke H. Autonomic cardiovascular control in conscious mice. Am J Physiol Regul Integr Comp Physiol 2000;279:R2214-R2221.
36. Tank J, Jordan J, Diedrich A, Obst M, Plehm R, Luft FC et al. Clonidine improves spontaneous baroreflex sensitivity in conscious mice through parasympathetic activation. Hypertension 2004;43:1042-1047.
37. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 2004;118:33-38.
38. Osaka T, Endo M, Yamakawa M, Inoue S. Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoa-drenal system. Peptides 2005;26:1623-1631.
39. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol 1999;403:261-280.
40. Neff RA, Wang J, Baxi S, Evans C, Mendelowitz D. Respiratory sinus arrhythmia: endogenous activation of nicotinic receptors mediates respiratory modulation of brainstem cardioinhibitory parasympathetic neurons. Circ Res 2003;93:565-572.
41. Robertson D. Primer on the Autonomic Nervous System. London/San Diego: Elsevier; 2004.
42. Lu CL, Zou X, Orr WC, Chen JD. Postprandial changes of sympathovagal balance measured by heart rate variability. Dig Dis Sci 1999;44:857-861.
43. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3:153-165.
44. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord;11:31-39.
45. Hull SS Jr, Vanoli E, Adamson PB, De Ferrari GM, Foreman RD, Schwartz PJ. Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine. Circulation 1995;91:2516-2519.
46. Routledge HC, Chowdhary S, Townend JN. Heart rate variability-a therapeutic target? J Clin Pharm Ther 2002;27:85-92.
47. Eckberg DL, Drabinsky M, Braunwald E. Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med 1971;285:877-883.
48. La Rovere MT, Specchia G, Mortara A, Schwartz PJ. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study. Circulation 1988;78:816-824.
49. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS Jr, Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-1481.